PL378400A1 - Zastosowanie nowego polimorfizmu w genie hsgk1 do diagnozowania nadciśnienia i zastosowanie rodziny genów sgk do diagnozowania i leczenia zespołu wydłużonego Q/T - Google Patents

Zastosowanie nowego polimorfizmu w genie hsgk1 do diagnozowania nadciśnienia i zastosowanie rodziny genów sgk do diagnozowania i leczenia zespołu wydłużonego Q/T

Info

Publication number
PL378400A1
PL378400A1 PL378400A PL37840004A PL378400A1 PL 378400 A1 PL378400 A1 PL 378400A1 PL 378400 A PL378400 A PL 378400A PL 37840004 A PL37840004 A PL 37840004A PL 378400 A1 PL378400 A1 PL 378400A1
Authority
PL
Poland
Prior art keywords
diagnosis
gene
hypertonia
syndrome
therapy
Prior art date
Application number
PL378400A
Other languages
English (en)
Inventor
Florian Lang
Andreas Busjahn
Original Assignee
Florian Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florian Lang filed Critical Florian Lang
Publication of PL378400A1 publication Critical patent/PL378400A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL378400A 2003-02-07 2004-02-05 Zastosowanie nowego polimorfizmu w genie hsgk1 do diagnozowania nadciśnienia i zastosowanie rodziny genów sgk do diagnozowania i leczenia zespołu wydłużonego Q/T PL378400A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10305213A DE10305213A1 (de) 2003-02-07 2003-02-07 Verwendung eines neuen Polymorphismus im hsgk1-Gen zur Diagnose der Hypertonie und Verwendung der sgk-Genfamilie zur Diagnose und Therapie des Long-Q/T-Syndroms

Publications (1)

Publication Number Publication Date
PL378400A1 true PL378400A1 (pl) 2006-04-03

Family

ID=32747646

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378400A PL378400A1 (pl) 2003-02-07 2004-02-05 Zastosowanie nowego polimorfizmu w genie hsgk1 do diagnozowania nadciśnienia i zastosowanie rodziny genów sgk do diagnozowania i leczenia zespołu wydłużonego Q/T

Country Status (14)

Country Link
US (1) US20080015141A1 (pl)
EP (1) EP1594983A2 (pl)
JP (1) JP2006520587A (pl)
KR (1) KR20050118672A (pl)
CN (1) CN1761760A (pl)
AU (1) AU2004209609A1 (pl)
BR (1) BRPI0407292A (pl)
CA (1) CA2515339A1 (pl)
DE (1) DE10305213A1 (pl)
MX (1) MXPA05008329A (pl)
PL (1) PL378400A1 (pl)
RU (1) RU2005127807A (pl)
WO (1) WO2004070057A2 (pl)
ZA (1) ZA200506283B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5071998B2 (ja) * 2005-08-25 2012-11-14 学校法人日本大学 本態性高血圧症の判定方法
WO2007025792A1 (de) * 2005-09-02 2007-03-08 Florian Lang Verfahren zur diagnose von hypertonie
EP2090588A4 (en) 2006-10-23 2010-04-07 Neocodex S L IN VITRO PROCEDURE FOR THE PROGNOSIS AND / OR DIAGNOSIS OF OVER SENSITIVITY TO ESTROGENIC OR SUBSTANCES WITH ESTROGENIC EFFECT
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
CN101892311B (zh) * 2010-06-01 2013-02-27 首都医科大学附属北京安贞医院 高血压易感基因的单核苷酸多态性位点rs7550536的检测方法及检测试剂盒
ES2894333T3 (es) 2013-09-26 2022-02-14 Beth Israel Deaconess Medical Ct Inc Inhibidores de SGK1 en el tratamiento del síndrome de QT Largo
TN2019000308A1 (en) 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
KR101992796B1 (ko) * 2018-02-19 2019-06-26 한국 한의학 연구원 Sgk1 유전자의 메틸화 수준을 이용한 고혈압의 예측 또는 진단을 위한 정보제공방법 및 이를 위한 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
EP1141003B9 (en) * 1998-12-14 2008-07-02 The University of Dundee Methods of activation of SGK by phosphorylation.
DE10113876A1 (de) * 2001-03-21 2002-09-26 Eberhard Karls Uni Medizinisch Quantitative diagnostische Analyse der Hypertonie
DE10225844A1 (de) * 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets

Also Published As

Publication number Publication date
WO2004070057A2 (de) 2004-08-19
AU2004209609A1 (en) 2004-08-19
BRPI0407292A (pt) 2006-01-31
US20080015141A1 (en) 2008-01-17
MXPA05008329A (es) 2005-09-30
DE10305213A1 (de) 2004-08-26
CN1761760A (zh) 2006-04-19
JP2006520587A (ja) 2006-09-14
ZA200506283B (en) 2006-05-31
EP1594983A2 (de) 2005-11-16
RU2005127807A (ru) 2006-03-20
CA2515339A1 (en) 2004-08-19
WO2004070057A3 (de) 2004-11-25
KR20050118672A (ko) 2005-12-19

Similar Documents

Publication Publication Date Title
IL219671A0 (en) 1,2- benzoxazoles and use thereof in the preparation of a medicament
GB2406928B (en) Facilitating and authenticating transactions
IL172316A0 (en) Novel compounds and their use in therapy
HK1078851A1 (en) 2-Indolinone-monoethanesulphonate and the use thereof in preparing a pharmaceutical composition
IL173576A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy
IL179795A0 (en) A pharmaceutical composition and its use
IL172507A0 (en) New biological entities and the pharmaceutical or diagnostic use thereof
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
IL197159A0 (en) Rna molecules and pharmaceutical compositions containing the same
IL175020A0 (en) Chemokine variants and their use
TWI368509B (en) Antituberculous therapeutic drugs and kit containing the same
EP1693005A4 (en) ULTRASONIC UNIT AND ULTRASOUND SURVEY
EP1731547A4 (en) POLYMERIZABLE COMPOUNDS AND USE THEREOF
IL178259A0 (en) Novel benzothiazoles and the use thereof as medicaments
GB0523576D0 (en) Drug composition and its use in therapy
ZA200703876B (en) 2-amido -4-phenylthiazole derivatives, the preparation and therapeutic use thereof
PL378400A1 (pl) Zastosowanie nowego polimorfizmu w genie hsgk1 do diagnozowania nadciśnienia i zastosowanie rodziny genów sgk do diagnozowania i leczenia zespołu wydłużonego Q/T
ZA200210316B (en) Composition and its therapeutic use.
GB0303663D0 (en) Assays and medical treatments
AU2003217421A8 (en) Prostate specific genes and the use thereof in design or therapeutics
AU2003255544A8 (en) Tumor specific oligosaccharide epitopes and use thereof
GB0326578D0 (en) Cancer diagnosis and therapy
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
ZA200707510B (en) Benzoxazocines and their therapeutic use
GB0411257D0 (en) Cassette and its use

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)